Differences in HER2-0 and HER2-low Breast Cancer: Androgen Receptor and Programmed Death Ligand 1 as Predictive Factors

• DOI: 10.4048/jbc.2024.0223
• Publication Date: 2025-02-24T00:43:51Z
• Authors: Xiaoqi Zhang; Ciqiu Yang; Yitian Chen; Junsheng Zhang; Peiyong Li; Na Huang; Yilin Chen; Minting Liang; Weiming Lv; Zhongyu Yuan; Jie Li; Kun Wang

Human epidermal growth factor receptor 2 (HER2)-low breast cancer has the potential to emerge as a distinct subtype. Several studies have compared differences between HER2-low and HER2-0 cancers, but no consensus been reached. Additionally, biomarker predict pathological complete response (pCR) rates in patients with remains be identified. We collected data from 777 across three centers, stratifying them into groups. survival pCR two groups investigated biomarkers that could reliably pCR. The study found had higher tumors (289 [30.1%] vs. 475 [18.1%], p < 0.0001). Survival analysis showed significant advantage for over cancers. Binary logistic revealed androgen (AR) expression predicts poorer both overall patient group (overall patients: odds ratio [OR], 0.479; 95% confidence interval [CI], 0.250-0.917; = 0.026 OR, 0.267; CI, 0.080-0.892; 0.032). In contrast, programmed death ligand 1 (PD-L1) was associated more favorable (OR, 3.199; 1.020-10.037; 0.046). There is currently insufficient evidence classify Our AR expression, along negative PD-L1 contributes lower rates.